Publications by authors named "Charlie Cao"

Claim this Profile
I
Influence Diagnostics of a Region of Interest in Multi-regional Clinical Trials.
Kazuhiko Kuribayashi, Charlie Cao

Ther Innov Regul Sci· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development and Validation of Clinical Scoring Tool to Predict Outcomes of Treatment With Vedolizumab in Patients With Ulcerative Colitis.
Parambir S Dulai, Siddharth Singh, Niels Vande Casteele, Joseph Meserve, Adam Winters, Charlie Cao

Clin Gastroenterol Hepatol· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adapting the Goal Attainment Approach for Major Depressive Disorder.
Maggie McCue, Sagar V Parikh, Lisa Mucha, Sara Sarkey, Charlie Cao

Neurol Ther· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Market Access Analysis of Biologics and Small-Molecule Inhibitors for Inflammatory Bowel Disease Among US Health Insurance Policies.
Parambir S Dulai, Mark T Osterman, Karen Lasch, Charlie Cao, Faisal Riaz

Dig Dis Sci· September 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Deep Remission With Vedolizumab in Patients With Moderately to Severely Active Ulcerative Colitis: A GEMINI 1 post hoc Analysis.
William J Sandborn, Jean-Frédéric Colombel, Remo Panaccione, Parambir S Dulai, Maria Rosario, Charlie Cao

J Crohns Colitis· February 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rapid Response to Vedolizumab Therapy in Biologic-Naive Patients With Inflammatory Bowel Diseases.
Brian G Feagan, Karen Lasch, Trevor Lissoos, Charlie Cao, Abigail M Wojtowicz

Clin Gastroenterol Hepatol· January 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A randomized trial of the efficacy and safety of azilsartan medoxomil combined with chlorthalidone.
Michael A Weber, Peter Sever, Attila Juhasz, Andrew Roberts, Charlie Cao

J Renin Angiotensin Aldosterone Syst· January 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Fasiglifam-Induced Liver Injury in Patients With Type 2 Diabetes: Results of a Randomized Controlled Cardiovascular Outcomes Safety Trial.
Venu Menon, A Michael Lincoff, Stephen J Nicholls, Susan Jasper, Kathy Wolski, Charlie Cao

Diabetes Care· December 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development and Validation of a Scoring System to Predict Outcomes of Vedolizumab Treatment in Patients With Crohn's Disease.
Parambir S Dulai, Brigid S Boland, Siddharth Singh, Khadija Chaudrey, Jenna L Koliani-Pace, Charlie Cao

Gastroenterology· September 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Combining the G-protein-coupled receptor 40 agonist fasiglifam with sitagliptin improves glycaemic control in patients with type 2 diabetes with or without metformin: A randomized, 12-week trial.
Xuejun V Peng, John F Marcinak, Marsha G Raanan, Charlie Cao

Diabetes Obes Metab· August 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of the angiotensin II receptor blocker azilsartan medoxomil in African-American patients with hypertension.
Wallace Johnson, William B White, Domenic Sica, George L Bakris, Michael A Weber, Charlie Cao

J Clin Hypertens (Greenwich)· July 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Impact of Azilsartan Medoxomil Treatment (Capsule Formulation) at Doses Ranging From 10 to 80 mg: Significant, Rapid Reductions in Clinic Diastolic and Systolic Blood Pressure.
Alfonso Perez, Charlie Cao

J Clin Hypertens (Greenwich)· March 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Azilsartan in Patients With Mild to Moderate Hypertension Using Clinic and Ambulatory Blood Pressure Measurements.
Alfonso Perez, Charlie Cao

J Clin Hypertens (Greenwich)· January 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Standardized Mixed-Meal Tolerance and Arginine Stimulation Tests Provide Reproducible and Complementary Measures of β-Cell Function: Results From the Foundation for the National Institutes of Health Biomarkers Consortium Investigative Series.
Sudha S Shankar, Adrian Vella, Ralph H Raymond, Myrlene A Staten, Roberto A Calle, Charlie Cao

Diabetes Care· September 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 2 study of TAK-442, an oral factor Xa inhibitor, in patients following acute coronary syndrome.
Sidney Goldstein, Eric R Bates, Deepak L Bhatt, Charlie Cao, David Holmes

Thromb Haemost· June 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of combining azilsartan medoxomil with amlodipine in patients with stage 2 hypertension.
Michael A Weber, William B White, Domenic Sica, George L Bakris, Charlie Cao

Blood Press Monit· April 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
TAK-875 versus placebo or glimepiride in type 2 diabetes mellitus: a phase 2, randomised, double-blind, placebo-controlled trial.
Charles F Burant, Prabhakar Viswanathan, John Marcinak, Charlie Cao, Majid Vakilynejad

Lancet· April 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of the novel angiotensin II receptor blocker azilsartan medoxomil vs valsartan by ambulatory blood pressure monitoring.
Domenic Sica, William B White, Michael A Weber, George L Bakris, Alfonso Perez, Charlie Cao

J Clin Hypertens (Greenwich)· July 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of the angiotensin receptor blocker azilsartan medoxomil versus olmesartan and valsartan on ambulatory and clinic blood pressure in patients with stages 1 and 2 hypertension.
William B White, Michael A Weber, Domenic Sica, George L Bakris, Alfonso Perez, Charlie Cao

Hypertension· March 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The comparative effects of azilsartan medoxomil and olmesartan on ambulatory and clinic blood pressure.
George L Bakris, Domenic Sica, Michael Weber, William B White, Andrew Roberts, Charlie Cao

J Clin Hypertens (Greenwich)· February 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A dose-finding study with TAK-442, an oral factor Xa inhibitor, in patients undergoing elective total knee replacement surgery.
Jeffrey I Weitz, Charlie Cao, Bengt I Eriksson, William Fisher, Stuart Kupfer

Thromb Haemost· December 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A randomized, double-blind, placebo-controlled trial of TAK-242 for the treatment of severe sepsis.
Todd W Rice, Arthur P Wheeler, Gordon R Bernard, Jean-Louis Vincent, Derek C Angus, Charlie Cao

Crit Care Med· August 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Oral antidiabetic drugs: bioavailability assessment of fixed-dose combination tablets of pioglitazone and metformin. Effect of body weight, gender, and race on systemic exposures of each drug.
Aziz Karim, Margaret Slater, Dawn Bradford, Lisa Schwartz, Zhen Zhao, Charlie Cao

J Clin Pharmacol· January 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Disposition kinetics and tolerance of escalating single doses of ramelteon, a high-affinity MT1 and MT2 melatonin receptor agonist indicated for treatment of insomnia.
Aziz Karim, Dwain Tolbert, Charlie Cao

J Clin Pharmacol· February 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis